208 related articles for article (PubMed ID: 35594370)
1. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
Peng F; Wang Y; Zhao J; Liu H; Liu Z; Ding K; Zhang H; Fu R
Br J Haematol; 2023 May; 201(3):417-421. PubMed ID: 35594370
[TBL] [Abstract][Full Text] [Related]
2. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
3. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
[TBL] [Abstract][Full Text] [Related]
4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
5. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
6. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
7. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.
Casey M; Tu C; Harrison SJ; Nakamura K
Blood Adv; 2022 Sep; 6(17):5165-5170. PubMed ID: 35830292
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
9. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
10. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
11. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
[TBL] [Abstract][Full Text] [Related]
12. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
13. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
14. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
15. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
16. Current use of bispecific antibodies to treat multiple myeloma.
Lee H; Neri P; Bahlis NJ
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
[TBL] [Abstract][Full Text] [Related]
17. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
Huo J; Huang Y; Zheng Z; Tay XN; Mahfut FB; Zhang W; Lam KP; Yang Y; Xu S
Antib Ther; 2022 Apr; 5(2):138-149. PubMed ID: 35774245
[TBL] [Abstract][Full Text] [Related]
18. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
20. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
